2023
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis
Strober B, Coates L, Lebwohl M, Deodhar A, Leibowitz E, Rowland K, Kollmeier A, Miller M, Wang Y, Li S, Chakravarty S, Chan D, Shawi M, Yang Y, Thaҫi D, Rahman P. Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis. Drug Safety 2023, 47: 39-57. PMID: 37906417, PMCID: PMC10764399, DOI: 10.1007/s40264-023-01361-w.Peer-Reviewed Original ResearchMeSH KeywordsAdultArthritis, PsoriaticBiological ProductsHumansNeoplasmsPsoriasisSeverity of Illness IndexTreatment OutcomeConceptsGuselkumab-treated patientsPlacebo-controlled periodBody mass indexPrior biologic usePsoriatic diseaseAE ratesSerious AEsBiologic usePsoriatic arthritisOpportunistic infectionsSerious infectionsPsoriasis studiesWeeks 0Clinical studiesWeek 4Phase II/III studyPhase II/III clinical studiesMajor adverse cardiovascular eventsLong-term safety profileBenefit/risk profileFavorable AE profilePlacebo-treated patientsAdverse cardiovascular eventsActive psoriatic arthritisSubgroup of patients
2022
Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry
Ogdie A, Harrison R, McLean R, Lin T, Lebwohl M, Strober B, Zhuo J, Patel V, Mease P. Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry. Journal Of The American Academy Of Dermatology 2022, 87: 1303-1311. PMID: 35987397, DOI: 10.1016/j.jaad.2022.07.060.Peer-Reviewed Original ResearchMeSH KeywordsArthritis, PsoriaticHumansProspective StudiesPsoriasisRegistriesSurveys and QuestionnairesConceptsPsoriasis Epidemiology Screening ToolBody mass indexProspective cohort studyPsoriasis RegistryCohort studyRheumatic Disease Comorbidity IndexOnset of PsAPatient-reported fatigueDevelopment of PsALogistic regression modelsComorbidity indexPsoriatic arthritisMass indexRisk model developmentArthritis riskPatientsScreening toolAlcohol usePSAUnique predictive modelsWork statusMisclassification biasCharacteristic curvePsoriasisRegistry
2019
Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from the US‐based Corrona Psoriasis Registry
Mease P, Palmer J, Hur P, Strober B, Lebwohl M, Karki C, Reed G, Etzel C, Greenberg J, Helliwell P. Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from the US‐based Corrona Psoriasis Registry. Journal Of The European Academy Of Dermatology And Venereology 2019, 33: 886-892. PMID: 30663130, PMCID: PMC6593969, DOI: 10.1111/jdv.15443.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedArthritis, PsoriaticCross-Sectional StudiesFemaleHumansMaleMiddle AgedPsoriasisRegistriesReproducibility of ResultsUnited StatesConceptsPsoriasis Epidemiology Screening ToolRegistry patientsPsoriatic arthritisActivity impairmentWorse health-related qualityDermatology Life Quality IndexScreening toolCorrona Psoriasis RegistryUndiagnosed psoriatic arthritisHealth-related qualityPatient-reported outcomesLife Quality IndexWorse health statusFive-item questionnaireChi-squared testCross-sectional analysisPsoriasis RegistryClinical characteristicsHigher BMIPatientsHealth statusPSAPEST scoresCategorical variablesArthritisJoint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities
Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal Of The American Academy Of Dermatology 2019, 80: 1073-1113. PMID: 30772097, DOI: 10.1016/j.jaad.2018.11.058.Peer-Reviewed Original ResearchMeSH KeywordsArthritis, PsoriaticCardiovascular DiseasesComorbidityDyslipidemiasEvidence-Based MedicineHumansHypertensionInflammatory Bowel DiseasesKidney DiseasesLife StyleLiver DiseasesLung Diseases, ObstructiveMental HealthMetabolic SyndromeNeoplasmsObesityPatient Education as TopicPhysician's RolePsoriasisQuality of LifeSleep Apnea SyndromesUstekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
Ghosh S, Gensler LS, Yang Z, Gasink C, Chakravarty SD, Farahi K, Ramachandran P, Ott E, Strober BE. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. Drug Safety 2019, 42: 751-768. PMID: 30739254, PMCID: PMC6520311, DOI: 10.1007/s40264-019-00797-3.Peer-Reviewed Original ResearchConceptsPlacebo-treated patientsPsoriatic arthritisRegistrational trialsCrohn's diseaseMajor adverse cardiovascular eventsUstekinumab-treated patientsAdverse cardiovascular eventsSevere plaque psoriasisConsistent safety profileSevere Crohn's diseaseActive psoriatic arthritisClinical development programUstekinumab doseCardiovascular eventsPlaque psoriasisBiologic agentsPsoriatic patientsInduction doseSafety profileIncidence rateSafety dataPatientsDiseaseSafety eventsWeeks
2016
Psoriasis in adults and children: Kids are not just little people
de Moll EH, Chang MW, Strober B. Psoriasis in adults and children: Kids are not just little people. Clinics In Dermatology 2016, 34: 717-723. PMID: 27968931, DOI: 10.1016/j.clindermatol.2016.07.006.Peer-Reviewed Original ResearchConceptsPediatric psoriasisPediatric populationLimited therapeutic armamentariumPrimary care providersCommon skin disorderAdult psoriasisYounger patientsTherapeutic armamentariumTreatment optionsSchool-aged childrenAppropriate treatmentCare providersPsoriasisSkin disordersIncurable diseasePsychosocial ramificationsPatientsAge childrenChildrenInherent risksPresentationChronicInfantsTherapyPopulationTreatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series
Klufas D, Wald J, Strober B. Treatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series. Pediatric Dermatology 2016, 33: 142-149. PMID: 26871417, DOI: 10.1111/pde.12782.Peer-Reviewed Original ResearchConceptsSevere pediatric psoriasisRetrospective case seriesPediatric psoriasisCase seriesSevere psoriasisSystemic therapySide effectsDisease responseSimilar side effect profilePhysician Global Assessment scaleComprehensive safety profileSmall sample sizeSingle referral centerSubjective side effectsSide effect profileSafety of treatmentMultiple treatment optionsAdverse event occurrenceComparison of efficacyGlobal Assessment ScalePaucity of dataAdult psoriasisImmunomodulating therapiesAdverse eventsReferral center
2014
Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis
Papp K, Menter A, Strober B, Kricorian G, Thompson E, Milmont C, Nirula A, Klekotka P. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. Journal Of The American Academy Of Dermatology 2014, 72: 436-439.e1. PMID: 25553889, DOI: 10.1016/j.jaad.2014.10.026.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedArthritis, PsoriaticDouble-Blind MethodHumansPsoriasisSeverity of Illness IndexConceptsSevere plaque psoriasisBiologic useHistory of PsAPlaque psoriasisDermatology Life Quality Index responseStatic Physician's Global Assessment scorePhysician Global Assessment scoreSafety of brodalumabPlacebo-controlled studySubgroup of patientsSeverity Index scoreSubpopulation of patientsGlobal assessment scoreSelf-reported historyPrior biologicsTreat populationPsoriasis AreaPsoriatic arthritisWeek 12Subset analysisNovel therapiesBrodalumabLife measuresPatientsPsoriasis
2012
Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases
de Souza A, Ali‐Shaw T, Reddy S, Fiorentino D, Strober B. Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases. British Journal Of Dermatology 2012, 168: 210-212. PMID: 23278559, DOI: 10.1111/j.1365-2133.2012.11206.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, Monoclonal, HumanizedArthritis, PsoriaticDermatologic AgentsHumansMalePsoriasisUstekinumabConceptsUstekinumab treatmentHuman immunoglobulin G1κ monoclonal antibodyChronic inflammatory skin conditionInflammatory skin conditionT helper 1Common p40 subunitT cell differentiationIL-23Inflammatory arthritisPsoriatic arthritisTh17 pathwayFamily historyP40 subunitSkin conditionsCell activationArthritisPsoriasisMonoclonal antibodiesPatientsTreatmentReportUstekinumabTh1InterleukinAntibodiesPSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.
Papp K, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. Journal Of Drugs In Dermatology 2012, 11: 1210-7. PMID: 23134986.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedArthritis, PsoriaticBody Mass IndexBody Surface AreaCardiovascular DiseasesData Interpretation, StatisticalFemaleHumansImmunologic FactorsInfliximabMaleMiddle AgedObesityPhototherapyProduct Surveillance, PostmarketingProspective StudiesPsoriasisRegistriesUstekinumabConceptsDisease-based registryBiologic agentsObservational studyMajor adverse cardiovascular eventsConventional systemic treatmentsGeneral psoriasis populationPsoriasis Longitudinal AssessmentAdverse cardiovascular eventsOverweight/obeseLong-term observational studyBody surface areaPsoriasis populationCardiovascular eventsCause mortalityAdverse eventsPsoriatic arthritisRegistry studySystemic agentsSystemic therapySystemic treatmentMedication historyDisease characteristicsSerious infectionsMean durationEfficacy data
2010
Disseminated superficial porokeratosis.
Brauer J, Mandal R, Walters R, Solomon G, Kundu R, Strober B. Disseminated superficial porokeratosis. Dermatology Online Journal 2010, 16: 20. PMID: 21163171, DOI: 10.5070/d395d16725.Peer-Reviewed Original ResearchConceptsPsoriatic arthritisSuperficial porokeratosisDiagnosis of porokeratosisOne-week historySetting of immunosuppressionDisseminated superficial porokeratosisCertolizumab pegolPruritic lesionsBiopsy specimenPorokeratosisArthritisDiagnosisPink spotsPegolImmunosuppressionPsoriasisMethotrexateTherapyLesionsExtremitiesWeeksWomen
2009
Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation
Menon K, Van Voorhees A, Bebo B, Gladman D, Hsu S, Kalb R, Lebwohl M, Strober B, Foundation P. Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation. Journal Of The American Academy Of Dermatology 2009, 62: 291-299. PMID: 19646777, DOI: 10.1016/j.jaad.2009.03.047.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHIV-associated psoriasisPotential adverse eventsPsoriatic arthritisAdverse eventsHIV infectionSevere diseaseTumor necrosis factor-alpha inhibitorsNecrosis factor-alpha inhibitorsNational Psoriasis Foundation Medical BoardFirst-line therapeutic agentsPlacebo-controlled trialSecond-line treatmentInfectious disease specialistsSafety of treatmentNational Psoriasis FoundationBenefits of treatmentMedical boardsOral retinoidsTopical therapyModerate diseaseCase seriesDisease specialistsImmunodeficiency virusTreatment options
2008
Effects of etanercept on C‐reactive protein levels in psoriasis and psoriatic arthritis
Strober B, Teller C, Yamauchi P, Miller J, Hooper M, Yang Y, Dann F. Effects of etanercept on C‐reactive protein levels in psoriasis and psoriatic arthritis. British Journal Of Dermatology 2008, 159: 322-330. PMID: 18503600, DOI: 10.1111/j.1365-2133.2008.08628.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsArthritis, PsoriaticBiomarkersBody Mass IndexC-Reactive ProteinDouble-Blind MethodEtanerceptFemaleHumansImmunoglobulin GMaleMiddle AgedPsoriasisReceptors, Tumor Necrosis FactorRetrospective StudiesSeverity of Illness IndexTumor Necrosis Factor-alphaConceptsC-reactive proteinBody mass indexEffect of etanerceptCRP levelsPsoriatic arthritisCRP valuesBaseline C-reactive proteinC-reactive protein levelsHigher body mass indexLower body mass indexBaseline CRP valuesBaseline PASI scoreSkin disease activityStatin drug useSevere plaque psoriasisBaseline CRP levelsElevated CRP levelsSeverity Index scoreEtanercept treatmentRegistrational studiesCRP elevationPlaque psoriasisCardiovascular riskDisease activityPASI score
2007
Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE.
Frankel E, Strober B, Crowley J, Fivenson D, Woolley J, Yu E, Xia H, Chiou C, Stevens S. Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE. Cutis 2007, 79: 322-6. PMID: 17500381.Peer-Reviewed Original Research
2006
Use of etanercept for psoriatic arthritis in the dermatology clinic: The Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study
Gottlieb A, Kircik L, Eisen D, Jackson J, Boh E, Strober B, Frankel E, Xia H, Stevens S. Use of etanercept for psoriatic arthritis in the dermatology clinic: The Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. Journal Of Dermatological Treatment 2006, 17: 343-352. PMID: 17853307, DOI: 10.1080/09546630600967166.Peer-Reviewed Original ResearchConceptsPsoriatic arthritisDermatology clinicBody surface area involvementGlobal assessmentTolerability of etanerceptPatient global assessmentPhysician global assessmentSerious adverse eventsUse of etanerceptSurface area involvementActive psoriatic arthritisWeeks of treatmentBody surface areaEtanercept treatmentExperience diagnosingEtanercept therapyPlaque psoriasisAdverse eventsJoint painArea involvementJoint diseaseDisease scorePatientsArthritisPsoriasis
2005
Off-Label Dermatologic Uses of Anti-TNF-a Therapies
Alexis A, Strober B. Off-Label Dermatologic Uses of Anti-TNF-a Therapies. Journal Of Cutaneous Medicine And Surgery 2005, 9: 296-302. PMID: 16699906, DOI: 10.1007/s10227-005-0110-7.Peer-Reviewed Original ResearchMeSH KeywordsAdalimumabAdolescentAdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedArthritis, PsoriaticChi-Square DistributionChildChild, PreschoolEtanerceptFemaleHumansImmunoglobulin GInfantInfliximabMalePsoriasisRandomized Controlled Trials as TopicReceptors, Tumor Necrosis FactorSkin DiseasesTime FactorsTumor Necrosis Factor-alphaConceptsDermatologic usesTNF inhibitorsDermatologic diseasesSneddon-Wilkinson diseaseInflammatory skin diseaseSmall case seriesNecrobiosis lipoidica diabeticorumPityriasis rubra pilarisMethodsA MEDLINE searchNumerous inflammatory skin diseasesIndividual case reportsApthous stomatitisBehçet's diseaseEosinophilic fasciitisSAPHO syndromeCase seriesCicatricial pemphigoidCrohn's diseaseMulticentric reticulohistiocytosisImmunomodulatory roleProinflammatory cytokinesCase reportLabel useMEDLINE searchSkin diseases
2004
Successful Treatment of Psoriasis and Psoriatic Arthritis With Etanercept and Methotrexate in a Patient Newly Unresponsive to Infliximab
Strober B. Successful Treatment of Psoriasis and Psoriatic Arthritis With Etanercept and Methotrexate in a Patient Newly Unresponsive to Infliximab. JAMA Dermatology 2004, 140: 366-366. PMID: 15023789, DOI: 10.1001/archderm.140.3.366.Peer-Reviewed Original ResearchEtanercept for the treatment of psoriasis: combination therapy with other modalities.
Strober B, Clarke S. Etanercept for the treatment of psoriasis: combination therapy with other modalities. Journal Of Drugs In Dermatology 2004, 3: 270-2. PMID: 15176161.Peer-Reviewed Original ResearchMeSH KeywordsAcitretinAdultAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsArthritis, PsoriaticCyclosporineDose-Response Relationship, DrugDrug Therapy, CombinationEtanerceptFemaleHumansImmunoglobulin GKeratolytic AgentsMaleMiddle AgedPsoriasisReceptors, Tumor Necrosis FactorRecombinant Fusion ProteinsConceptsTumor necrosis factorTumor necrosis factor receptorWeekly doseRheumatoid arthritisPatients of psoriasisPlacebo-controlled studySevere plaque psoriasisSelf-administered medicationsJuvenile rheumatoid arthritisTreatment of psoriasisHuman fusion proteinNecrosis factor receptorPlaque psoriasisContinuous therapyPsoriasis AreaPsoriatic arthritisSystemic therapyPsoriasis patientsTreatment regimenClinical efficacyCombination therapyMedical historyClinical trialsNecrosis factorEtanercept